TYK2 and in situ carcinoma: showed that CIS samples had a 46-gene expression signature in which the druggable targets MTOR, TYK2, AXIN1, CTP1B, GAK, and PIEZO1 were selectively upregulated while BRD2 and NDUFB2 were selectively downregulated (107).